US FDA approves first-in-class treatment for kidney disease

As a condition of the accelerated approval, the ongoing clinical trial must be completed to confirm that Trutakna slows kidney function decline over the long-term in patients with IgA nephropathy.

The United States Food and Drug Administration (US FDA) has approved Trutakna (atacicept-vymj), a first-in-class treatment developed by Vera Therapeutics, to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.

As a condition of the accelerated approval, the ongoing clinical trial must be completed to confirm that the drug slows kidney function decline over the long term.